Ross Moat's Insider Trades & SAST Disclosures
Ross Moat's most recent trade in Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A was a trade of 1,118 Class A Ordinary Share done at an average price of $16 . Disclosure was reported to the exchange on March 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ross Moat.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 16.00 per share. | 16 Mar 2025 | 1,118 | 22,854 (0%) | 0% | 16 | 17,888 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 994 | 23,848 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 994 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 292 | 23,556 (0%) | 0% | 22.6 | 6,602 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.10 per share. | 15 Jul 2024 | 67,346 | 22,896 (0%) | 0% | 26.1 | 1,757,731 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 36,100 | 36,100 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 29,730 | 18,534 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.10 per share. | 15 Jul 2024 | 29,730 | 65,466 (0%) | 0% | 11.1 | 330,003 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 24,776 | 30,924 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.97 per share. | 15 Jul 2024 | 24,776 | 90,242 (0%) | 0% | 12.0 | 296,569 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 14,000 | 0 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.83 per share. | 15 Jul 2024 | 14,000 | 35,736 (0%) | 0% | 8.8 | 123,620 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 6,962 | 6,962 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 4,089 | 22,480 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,477 | 4,954 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 1,612 | 4,833 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 15 Jul 2024 | 1,393 | 21,087 (0%) | 0% | 26.7 | 37,249 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.12 per share. | 15 Jul 2024 | 1,160 | 21,736 (0%) | 0% | 27.1 | 31,459 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 994 | 994 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 994 | 22,081 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 15 Jul 2024 | 345 | 21,736 (0%) | 0% | 26.7 | 9,225 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 15.65 per share. | 15 Jul 2024 | 211 | 18,391 (0%) | 0% | 15.6 | 3,302 | Class A Ordinary Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 36,100 | 36,100 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 6,962 | 11,795 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 5,569 | 5,569 | - | - | Performance Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,477 | 9,318 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 2,477 | 17,629 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.90 per share. | 04 Apr 2024 | 1,353 | 16,276 (0%) | 0% | 17.9 | 24,219 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,612 | 4,833 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,612 | 16,032 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.70 per share. | 01 Apr 2024 | 880 | 15,152 (0%) | 0% | 19.7 | 17,336 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 2,477 | 13,906 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 2,477 | 7,431 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.71 per share. | 10 Apr 2023 | 1,353 | 12,553 (0%) | 0% | 10.7 | 14,491 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 38,668 | 38,668 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 6,445 | 6,445 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 2,137 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 2,137 | 12,596 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 15 Jan 2023 | 1,844 | 10,008 (0%) | 0% | 9.6 | 17,629 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.12 per share. | 15 Jan 2023 | 1,167 | 11,429 (0%) | 0% | 11.1 | 12,977 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 994 | 11,002 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2023 | 994 | 1,988 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.46 per share. | 15 Jan 2023 | 543 | 10,459 (0%) | 0% | 11.5 | 6,223 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 59,460 | 59,460 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 9,908 | 9,908 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 995 | 8,727 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 995 | 2,982 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.44 per share. | 01 Sep 2022 | 563 | 8,164 (0%) | 0% | 11.4 | 6,441 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 9.56 per share. | 01 Sep 2022 | 360 | 7,732 (0%) | 0% | 9.6 | 3,442 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 59,460 | 59,460 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2022 | 9,908 | 9,908 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 2,270 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2022 | 2,270 | 8,612 (0%) | 0% | - | Class A Common Share | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.98 per share. | 21 Mar 2022 | 1,240 | 7,372 (0%) | 0% | 11.0 | 13,615 | Class A Common Share |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | ARCALYST General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 7,954 | 7,954 | - | - | Share Option | |
| Kiniksa Pharmaceuticals Lt... | Ross Moat | ARCALYST General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Sep 2021 | 3,977 | 3,977 | - | - | Restricted Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges